Products
Pegloticase is commercially available as a concentrate for the preparation of an infusion solution (Krystexxa). The drug is not currently registered in many countries.
Structure and properties
Pegloticase is a recombinant uricase conjugated to mPEG (monomethoxypolyethylene glycol). It is obtained from genetically modified using biotechnological methods. The active ingredient has a molecular weight of 545 kDa. Uricase is found in bacteria and many mammals, but not in humans because the corresponding gene is not functional in us.
Effects
Pegloticase (ATC M04AX02) promotes the breakdown of uric acid to the water-soluble metabolite allantoin, which is excreted by the kidney.
Indications
As a second-line agent for treatment of severe gout.
Dosage
According to the SmPC. The drug is injected every two weeks as an intravenous infusion.
Contraindications
- Hypersensitivity
- Glucose-6-phosphate dehydrogenase deficiency and other cellular metabolic disorders that may cause hemolysis and methemoglobinemia.
For complete precautions, see the drug label.
Adverse effects
The most common possible adverse effects include nausea, skin reactions, an acute gout attack, and infusion-related reactions. Severe allergic reactions may occur (anaphylaxis).
